Global Ganja Report

The Justice Department and Drug Enforcement Administration announced April 23 that FDA-approved marijuana products and medical marijuana products covered by a qualifying state-issued license have been moved to Schedule III of the Controlled Substances Act, a significant loosening of federal restrictions on the drug for medical use.

The order, issued by Acting Attorney General Todd Blanche, carries out President Donald Trump's Dec. 18, 2025 executive order calling for expanded research into medical marijuana and cannabidiol.

President Donald Trump signed an executive order Dec. 18 to accelerate the reclassification of marijuana, a move that would ease decades-old restrictions that have classified the drug alongside heroin as having no accepted medical value.

The US Controlled Substances Act ranks drugs along a five-tier spectrum based on their potential for abuse and recognized medical value. Schedule I drugs are those with a high likelihood of abuse, no accepted medical use, and considerable health risks even when administered under medical supervision. Since 1970, marijuana has been listed alongside heroin as a Schedule I drug. Schedule V drugs are those with accepted medical uses and a relatively low likelihood of abuse.

As their name implies, World Breeders is a cannabis seed company with a planetary consciousness. Co-director Gorka Cid Luaces says he is proud of the founders' trajectory from the "underground side" to an enterprise with operations on three continents, and an ambition to "export THC seed worldwide."

California's Oaksterdam University has announced the passing of its founder and longtime activist Richard Lee. As an entrepreneur, Lee opened some of the first Amsterdam-style cannabis coffeeshops in the United States, years before statewide legalization in California—the Blue Sky Coffeeshop and Bulldog Coffeeshop, both in an area near downtown Oakland that became known as "Oaksterdam." He founded Oaksterdam University in 2007, the first brick-and-mortar establishment to offer in-person educational training to those seeking to enter the cannabis industry. The University has graduated over 110,000 students.

In a last-minute move before the measure was to automatically become law, Gov. Greg Abbott on June 23 vetoed Senate Bill 3, which sought to ban the sale of all THC-laden products in Texas, whether Delta-8 and Delta-9. The bill would have also placed greater restrictions on CBD products, such as banning their sale to those under 21. Abbott has called for a special legislative session to revisit the question, which has pitted the hemp industry against the GOP establishment. Abbott's own Lt. Gov. Dan Patrick was a key advocate of the "THC ban." Patrick bashed Abbott over the veto, saying he "wants to legalize recreational marijuana."

Thailand's government on June 26 approved new measures restricting the sale of cannabis to those with a doctor's prescription, in the hope of reining in an industry that officials see as out of control. The public health ministry also says that consumption of cannabis is to be re-criminalized, although a date for that has not been set.

The White House FY2026 budget request calls for the repeal of a long-standing federal rider that prohibits the Justice Department from using taxpayer dollars to prosecute patients and others involved in the state-legal medical cannabis industry. The provision, which has been in place since 2014, protects patients, caregivers and medical cannabis providers in the 39 states that have legalized medical access from federal interference or criminal prosecution. Prior to the passage of this protection, federal prosecutors routinely took actions against patients and dispensaries in legal states.

In the big — and, in nearly half of US states now, successful — drive to legalize cannabis, two major arguments have been brought to bear. First, that public oversight of a legal industry will assure transparency and standards for quality. And secondly, that a taxed industry will be a boon to state and local economies.

But now a disturbing new study from an industry advocacy group in California indicates that the legal cannabis sector faces a challenge in the proliferation of ostensibly legal but in fact unregulated psychoactive “hemp” products.